0.66
-3.65%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oncosil Medical
Its shares trade on ASX under the ticker OSL.AX. It has been listed since 15 August 2005. In the fiscal year to 30 June 2026, it reported revenue of A$1.7m and a net loss of A$10.9m. At that date it held total assets of A$10.3m and shareholders' equity of A$5.0m.
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is engaged in the development of its lead product candidate, the OncoSil localized radiation therapy, for the treatment of pancreatic cancer. The firm's lead product, OncoSil, is a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor. OncoSil is a silicon and phosphorus (p32) beta emitter, able to be implanted intra-tumorally via endoscopic ultrasonography in localized solid tumors of patients with pancreatic cancer. The firm focuses on an application for Conformite Europeene (CE) Mark to enable commercial sales of OncoSil in the European Union and an application for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to enable commencement of the United States pivotal clinical study, known as OncoPac-1.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 15 Aug 2005
- Employees
- 2
- Website
- oncosil.com.au ↗
Leadership
Pay as last reported
- Mr. Douglas CubbinNon-Executive Chairman of the Board
- Mr. Nigel LangeChief Executive Officer, Managing Director, Executive Director, since 2021A$608,489
- Mr. Christian CinChief Financial Officer, Company Secretary
- Mr. Peter HallNon-Executive Director
- Mr. Gabriel LiberatoreNon-Executive Director
- Ms. Lelde SmitsNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oncosil Medical Ltd has a proprietary medical technology that has shown potential in treating various types of solid tumors.
- The company has a strong intellectual property portfolio, including patents and trademarks, which provides a competitive advantage.
- Oncosil has a dedicated and experienced team of researchers and medical professionals who are committed to advancing the field of oncology.
Weaknesses
- The company is currently in the early stages of development and has not yet commercialized its technology, which creates financial uncertainties.
- Oncosil Medical Ltd heavily relies on external funding to support its research and development efforts, making it vulnerable to market fluctuations.
- The regulatory approval process for medical devices and treatments can be lengthy and costly, posing potential delays and obstacles for the company.
Opportunities
- The global oncology market is experiencing significant growth, driven by increasing cancer rates and advancements in medical technology, presenting a favorable market environment for Oncosil.
- Partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and accelerate the commercialization process.
- Expansion into international markets, particularly regions with high cancer prevalence, offers the potential for increased revenue and market share.
Threats
- Competition in the oncology space is intense, with numerous established companies and startups vying for market share.
- Changes in healthcare regulations and reimbursement policies may impact the adoption and pricing of Oncosil's technology.
- Failure to meet clinical trial endpoints or demonstrate the efficacy and safety of its products could hinder regulatory approvals and market acceptance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.